Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 1, 2000, Pages 51-56

  Yoshisue, Kunihiro ^a   Hironaga, Kazue ^a   Yamaguchi, Syuji ^a   Yamamoto, Akira ^a   Nagayama, Sekio ^a   Kawaguchi, Yasuro ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Gastrointestinal toxicity; Ileum; Potassium oxonate; S 1; Thymidylate synthase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLOXURIDINE PHOSPHATE; FLUOROURACIL; FLUOROURIDINE PHOSPHATE; METHYLENETETRAHYDROFOLIC ACID; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXONATE POTASSIUM; TEGAFUR; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; URIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INACTIVATION; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; MALE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT;

EID: 0033918075     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000123     Document Type: Article

References (27)

1. 1. Pinedo HH, Peters GFJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653
2. 2. Heidelberger C (1975) Fluorinated pyrimidines and their nucleosides. In: AC Startorelli, D Johns (eds) Antineoplastic and immunosuppressive agents. Handbook of experimental pharmacology. Springer-Verlag, New York, p 193
3. 3. Heidelberger C, Dannenberg PV, Moran RG (1989) Fluorinated pyrimidines and their nucleosides. Adv Enzymol Relat Areas Mol Biol 54: 57
4. 4. Lokich JJ, Ahlgren JD, Gullo JJ, Phillips JG, Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7: 425
5. 5. Caballero GA, Ausman RK, Quebbeman EJ (1985) Long-term, ambulatory, continuous iv infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep 69: 13
6. 6. Quebbeman E, Ausman R, Hansen R, Becker T, Caballero GA, Ritch P, Jenkins D, Blake D, Tangen L, Schulte W (1985) Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. J Surg Oncol 30: 60
7. 7. Wade JL, Herbst S, Greenburg A (1986) Prolonged venous infusion (PVI) of 5-fluorouracil (5-FU) for metastatic colon cancer (MCC). In: Leventhal B (ed) Proceedings of the 22nd Annual Meeting of the American Society of Clinical Oncology, vol 5. American Society of Clinical Oncology, Los Angeles, p 341
8. 8. Hansen R, Quebbeman E, Beatty P, Ritch P, Andersen T, Jenkins D, Frick J, Ausman R (1987) Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat 10: 145
9. 9. Moynihan T, Hansen R, Anderson T, Quebbeman E, Beatty P, Ausman R, Ritch P, Chitamber C, Vukelich M (1988) Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 11: 461
10. 10. Barbounis VP, Kalofonos HP, Munro AJ, McKenzie CG, Sackier JM, Epenetos AA (1989) Treatment of colorectal cancer and other malignancies with continuous infusion of 5-fluorouracil. Anticancer Res 9: 33
11. 11. Huan S, Pazdur R, Singhakowinta A, Samal B, Vaitkevicius VR (1989) Low-dose continuous infusion 5-fluorouracil, evaluation in advanced breast carcinoma. Cancer 63: 419
12. 12. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215
13. 13. Shirasaka T, Nakano K, Takechi T, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M (1996) Antitumor activity of 1 M tegafur-0.4 M chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602
14. 14. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39: 205
15. 15. Shirasaka T, Fukushima M, Shimamoto Y, Kimura K (1993) Preclinical studies on S-1, a new oral tegafur plus modulator: optimal molar ratio and antiactivity. In: Einhorn J, Nord CE, Norrby SR (eds) Proceedings of the 18th International Congress of Chemotherapy. American Society for Microbiology, Stockholm, p 927
16. 16. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004
17. 17. Jackman AL, Jones TR, Calvert AH (1985) Thymidylate synthase inhibitors: experimental and clinical aspects. In: FM Muggia (ed) Experimental and clinical progress in cancer chemotherapy. Martinus Nijhoff, Boston, p 155
18. 18. Danenberg PV (1977) Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473: 73
19. 19. Langenbach RJ, Danenberg PV, Heidelberger C (1972) Thymidylate synthetase: mechanism of inhibition by 5-fluoro 2′-deoxyuridylate. Biochem Biophys Res Commun 48: 1565
20. 20. Santi DV, McHenry CS, Sommer H (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13: 471
21. 21. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248
22. 22. Houghton JA, Houghton PJ, Wooten RS (1979) Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2′-deoxyuridine. Cancer Res 39: 2406
23. 23. Washtien WL (1983) Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil. Mol Pharmacol 25: 171
24. 24. Wilt CL van der, Pinedo HM, Smid K, Peters GJ (1992) Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 52: 4922
25. 25. Roy van Zuidewijn DBW de, Schillings PHM, Wobbes T, Hendriks T, Boer HHM de (1992) Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats. Exp Mol Pathol 56: 96
26. 26. Berne MHO, Gustausson BG, Almersjo O, Spears PC, Frosing R (1986) Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma. Cancer Chemother Pharmacol 16: 237
27. 27. Laar JA van, Wilt CL van der, Rustum YM, Noordhuis P, Smid K, Pinedo HM, Peters GJ (1996) Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model. Clin Cancer Res 2: 1327